Single nucleotide polymorphism microarray analysis in cortisol-secreting adrenocortical adenomas identifies new candidate genes and pathways1,2

Neoplasia

Volumn 14, Issue 3, 2012, Pages 206-218

  Ronchi, Cristina L ^a   Leich, Ellen ^b   Sbiera, Silviu ^a   Weismann, Dirk ^a   Rosenwald, Andreas ^b   Allolio, Bruno ^a   Fassnacht, Martin ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE SYNTHASE; EPHRIN RECEPTOR A7; FRAGILE HISTIDINE TRIAD PROTEIN; HYDROCORTISONE; MESSENGER RNA; NOTCH1 RECEPTOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SOMATOMEDIN B RECEPTOR;

ADRENAL CORTEX ADENOMA; ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; CTNNB1 GENE; CYP11B1 GENE; DNA MICROARRAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HETEROZYGOSITY LOSS; HRAS GENE; HUMAN; HUMAN TISSUE; HYDROCORTISONE RELEASE; MALE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEROIDOGENESIS; STIL GENE;

EID: 84859116630     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111758     Document Type: Article

References (55)

1. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, and Bornstein SR (2004). The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25, 309-340.
2. Fassnacht M, Libe R, Kroiss M, and Allolio B (2011). Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 7, 323-335.
3. Bernard MH, Sidhu S, Berger N, Peix JL, Marsh DJ, Robinson BG, Gaston V, Le Bouc Y, and Gicquel C (2003). A case report in favor of a multistep adrenocortical tumorigenesis. J Clin Endocrinol Metab 88, 998-1001.
4. Barzon L, Sonino N, Fallo F, Palu G, and Boscaro M (2003). Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149, 273-285.
5. Bassett MH, Mayhew B, Rehman K, White PC, Mantero F, Arnaldi G, Stewart PM, Bujalska I, and Rainey WE (2005). Expression profiles for steroidogenic enzymes in adrenocortical disease. J Clin Endocrinol Metab 90, 5446-5455.
6. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, et al. (2001). Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86, 117-123.
7. Ragazzon B, Assie G, and Bertherat J (2011). Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer 18, R15-R27.
8. Stratakis CA (2009). New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors. Mol Cell Endocrinol 300, 152-157.
9. Sidhu S, Gicquel C, Bambach CP, Campbell P, Magarey C, Robinson BG, and Delbridge LW (2003). Clinical and molecular aspects of adrenocortical tumourigenesis. ANZ J Surg 73, 727-738.
10. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, et al. (2001). Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61, 6762-6767.
11. Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libe R, Rene-Corail F, Audebourg A, Vacher-Lavenu MC, et al. (2011). Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab 96, E419-E426.
12. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, Chokri I, Audebourg A, Royer B, Sbiera S, et al. (2011). β-Catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 17, 328-336.
13. Tadjine M, Lampron A, Ouadi L, and Bourdeau I (2008). Frequent mutations of β-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 68, 264-270.
14. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, and Lichter P (2000). Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28, 145-152.
15. Sidhu S, Marsh DJ, Theodosopoulos G, Philips J, Bambach CP, Campbell P, Magarey CJ, Russell CF, Schulte KM, Roher HD, et al. (2002). Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 87, 3467-3474.
16. Zhao J, Speel EJ, Muletta-Feurer S, Rutimann K, Saremaslani P, Roth J, Heitz PU, and Komminoth P (1999). Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 155, 1039-1045.
17. Gruschwitz T, Breza J, Wunderlich H, and Junker K (2010). Improvement of histopathological classification of adrenal gland tumors by genetic differentiation. World J Urol 28, 329-334.
18. Kjellman M, Kallioniemi OP, Karhu R, Hoog A, Farnebo LO, Auer G, Larsson C, and Backdahl M (1996). Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 56, 4219-4223.
19. Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, and Komminoth P (2002). Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 34, 48-57.
20. Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM, and Demeure MJ (2008). Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 7, 425-431.
21. Szabo PM, Tamasi V, Molnar V, Andrasfalvy M, Tombol Z, Farkas R, Kovesdi K, Patocs A, Toth M, Szalai C, et al. (2010). Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene 29, 3163-3172.
22. LaFramboise T (2009). Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res 37, 4181-4193.
23. Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, Grigorova M, Jones KW, Wei W, Stratton MR, et al. (2004). High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 14, 287-295.
24. Dutt A and Beroukhim R (2007). Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol 19, 43-49.
25. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, and Montori VM (2008). The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93, 1526-1540.
26. Fassnacht M, Beuschlein F, Quinkler M, and Petersenn S (2010). Arterial hypertension and subclinical Cushing's syndrome [in German]. MMW Fortschr Med 152, 39-41.
27. Cheung KJ, Delaney A, Ben-Neriah S, Schein J, Lee T, Shah SP, Cheung D, Johnson NA, Mungall AJ, Telenius A, et al. (2010). High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer 49, 669-681.
28. Choy KW, Setlur SR, Lee C, and Lau TK (2010). The impact of human copy number variation on a new era of genetic testing. BJOG 117, 391-398.
29. Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc B Met 57, 289-300.
30. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, et al. (2009). STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37, D412-D416.
31. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, et al. (2011). The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39, D561-D568.
32. Haralambieva E, Kleiverda K, Mason DY, Schuuring E, and Kluin PM (2002). Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol 198, 163-170.
33. LeBron C, Pal P, Brait M, Dasgupta S, Guerrero-Preston R, Looijenga LH, Kowalski J, Netto G, and Hoque MO (2011). Genome-wide analysis of genetic alterations in testicular primary seminoma using high resolution single nucleotide polymorphism arrays. Genomics 97, 341-349.
34. Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, and Baretton GB (2008). Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density Affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 10, 634-642.
35. Chari R, Coe BP, Vucic EA, Lockwood WW, and Lam WL (2010). An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. BMC Syst Biol 4, 67.
36. Pfaffl MW (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45.
37. Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, et al. (2010). High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 95, E161-E171.
38. Lobry C, Oh P, and Aifantis I (2011). Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 208, 1931-1935.
39. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Maciel CC, Mattos GE, Jorge AA, et al. (2008). Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 93, 3524-3531.
40. Yashiro T, Hara H, Fulton NC, Obara T, and Kaplan EL (1994). Point mutations of ras genes in human adrenal cortical tumors: absence in adrenocortical hyperplasia. World J Surg 18, 455-460; discussion 460-451.
41. Patterson EE, Holloway AK, Weng J, Fojo T, and Kebebew E (2011). MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117, 1630-1639.
42. Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, Seggewiss J, Willscher E, Walz MK, Worm K, and Schmid KW (2011). Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol 64, 529-535.
43. Pasquale EB (2010). Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10, 165-180.
44. El Wakil A and Lalli E (2011). The Wnt/β-catenin pathway in adrenocortical development and cancer. Mol Cell Endocrinol 332, 32-37.
45. Artunc F, Sandulache D, Nasir O, Boini KM, Friedrich B, Beier N, Dicks E, Potzsch S, Klingel K, Amann K, et al. (2008). Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARγ agonist pioglitazone. Pflugers Arch 456, 425-436.
46. Amato R, D'Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C, Costa N, Bellacchio E, Mattarocci S, Fuiano G, et al. (2009). Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J Mol Med (Berl) 87, 1221-1239.
47. Lang F, Perrotti N, and Stournaras C (2010). Colorectal carcinoma cellsregulation of survival and growth by SGK1. Int J Biochem Cell Biol 42, 1571-1575.
48. Reiter MH, Vila G, Knosp E, Baumgartner-Parzer SM, Wagner L, Stalla GK, and Luger A (2011). Opposite effects of serumand glucocorticoid-regulated kinase-1 and glucocorticoids on POMC transcription and ACTH release. Am J Physiol Endocrinol Metab 301, E336-E341.
49. Miyata S, Koyama Y, Takemoto K, Yoshikawa K, Ishikawa T, Taniguchi M, Inoue K, Aoki M, Hori O, Katayama T, et al. (2011). Plasma corticosterone activates SGK1 and induces morphological changes in oligodendrocytes in corpus callosum. PLoS One 6, e19859.
50. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, and Vallon V (2006). (Patho)physiological significance of the serumand glucocorticoid-inducible kinase isoforms. Physiol Rev 86, 1151-1178.
51. Tyybakinoja A, Elonen E, Vauhkonen H, Saarela J, and Knuutila S (2008). Single nucleotide polymorphism microarray analysis of karyotypically normal acute myeloid leukemia reveals frequent copy number neutral loss of heterozygosity. Haematologica 93, 631-632.
52. Hayward P, Brennan K, Sanders P, Balayo T, DasGupta R, Perrimon N, and Martinez Arias A (2005). Notch modulates Wnt signalling by associating with Armadillo/β-catenin and regulating its transcriptional activity. Development 132, 1819-1830.
53. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M, and Liu ZJ (2005). Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression. J Clin Invest 115, 3166-3176.
54. Failor KL, Desyatnikov Y, Finger LA, and Firestone GL (2007). Glucocorticoid-induced degradation of glycogen synthase kinase-3 protein is triggered by serumand glucocorticoid-induced protein kinase and Akt signaling and controls β-catenin dynamics and tight junction formation in mammary epithelial tumor cells. Mol Endocrinol 21, 2403-2415.
55. Mo JS, Ann EJ, Yoon JH, Jung J, Choi YH, Kim HY, Ahn JS, Kim SM, Kim MY, Hong JA, et al. (2011). Serum and glucocorticoid-inducible kinase 1 (SGK1) controls Notch1 signaling by downregulation of protein stability through Fbw7 ubiquitin ligase. J Cell Sci 124, 100-112.